Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 441

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.

A safe and potent anti-CD19 CAR T cell therapy

Open access
Ying, Zhitao, Huang, Xue F., Xiang, Xiaoyu, Liu, Yanling, Kang, Xi, Song, Yuqin, Guo, Xiaokai, Liu, Hanzhi, Ding, Ning, Zhang, Tingting, Duan, Panpan, Lin, Yufu, Zheng, Wen, Wang, Xiaopei, Lin, Ningjing, Tu, Meifeng, Xie, Yan, Zhang, Chen, Liu, Weiping, Deng, Lijuan, Gao, Shunyu, Ping, Lingyan, Wang, Xuejuan, Zhou, Nina, Zhang, Junqing, Wang, Yulong, Lin, Songfeng, Mamuti, Mierzhati, Yu, Xueyun, Fang, Lizhu, Wang, Shuai, Song, Haifeng, Wang, Guan, Jones, Lindsey, Zhu, Jun, Chen, Si-Yi · 2019 · Nature Medicine

Abstract

Anti-CD19 chimeric antigen receptor (CAR) T cell therapies can cause severe cytokine-release syndrome (CRS) and neurotoxicity, impeding their therapeutic application. Here we generated a new anti-CD19 CAR molecule (CD19-BBz(86)) derived from the CD19-BBz prototype bearing co-stimulatory 4-1BB and CD3ζ domains. We found that CD19-BBz(86) CAR T cells produced lower levels of cytokines, expressed higher levels of antiapoptotic molecules and proliferated more slowly than the prototype CD19-BBz CAR T cells, although they retained potent cytolytic activity. We performed a phase 1 trial of CD19-BBz(86) CAR T cell therapy in patients with B cell lymphoma (ClinicalTrials.gov identifier NCT02842138). Complete remission occurred in 6 of 11 patients (54.5%) who each received a dose of 2 × 108–4 × 108 CD19-BBz(86) CAR T cells. Notably, no neurological toxicity or CRS (greater than grade 1) occurred in any of the 25 patients treated. No significant elevation in serum cytokine levels after CAR T cell infusion was detected in the patients treated, including in those who achieved complete remission. CD19-BBz(86) CAR T cells persistently proliferated and differentiated into memory cells in vivo. Thus, therapy with the new CD19-BBz(86) CAR T cells produces a potent and durable antilymphoma response without causing neurotoxicity or severe CRS, representing a safe and potent anti-CD19 CAR T cell therapy. A new anti-CD19 CAR T cell therapy induces potent antitumor responses without causing severe cytokine-release syndrome or neurotoxicity in patients with lymphoma.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-019-0421-7

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 45 references

Cited by

See all 441

Metadata

Authors
Ying, Z., Huang, X. F., Xiang, X., Liu, Y., Kang, X., Song, Y., Guo, X., Liu, H., Ding, N., Zhang, T., Duan, P., Lin, Y., Zheng, W., Wang, X., Lin, N., Tu, M., Xie, Y., Zhang, C., Liu, W., Deng, L., Gao, S., Ping, L., Wang, X., Zhou, N., Zhang, J., Wang, Y., Lin, S., Mamuti, M., Yu, X., Fang, L., Wang, S., Song, H., Wang, G., Jones, L., Zhu, J., & Chen, S.-Y.
Venue
Nature Medicine
Published
2019-04-22
Volume
25
Issue
6
Pages
947-953
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W2936551248
Cited by
441
References
45
FWCI
22.04
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A safe and potent anti-CD19 CAR T cell therapy. https://app.cochat.ai/papers/10.1038/s41591-019-0421-7
The paper
Ying, Z., Huang, X. F., Xiang, X., Liu, Y., Kang, X., Song, Y., Guo, X., Liu, H., Ding, N., Zhang, T., Duan, P., Lin, Y., Zheng, W., Wang, X., Lin, N., Tu, M., Xie, Y., Zhang, C., Liu, W., . . . Chen, S.-Y. (2019). A safe and potent anti-CD19 CAR T cell therapy. Nature Medicine. https://doi.org/10.1038/s41591-019-0421-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.